Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Forte Biosciences Inc

FBRX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: N/A

Last Close

$76.99

▲ +0.00%

Market Cap $1.63B · Vol 208.67K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.63B

Small Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

70.83

Momentum

Beta

2.63

vs Market

52W High

$77.19

0.26% below

52W Low

$10.30

647.48% above

Volume

208.67K

Avg 428.49K

P/B

5.79

Price-to-book

ROE

N/A

Return on equity

Free Float

90.96%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Forte Biosciences Inc (FBRX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does FBRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.13%

+0.64%

+258.59%

+154.77%

YTD

+182.32%

+589.87%

+263.33%

-89.08%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-69,375,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-94.69% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.79
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	21.23M

Technical Indicators

50-Day SMA	$53.93
200-Day SMA	$32.54
RSI (14)	70.83
Beta	2.63
52-Week High	$77.19
52-Week Low	$10.30

Volume Today	208.67K
Avg Daily Volume (30D)	428.49K
Relative Volume	0.49x
Volatility (10D)	0.50
Volatility (30D)	106.56
Free Float	90.96%

Analyst Consensus

N/A

Current Price $76.99

Mean Target N/A

52W Low$10.30 52W High$77.19

Current

Target

$10.30 $77.19

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001V0GC53

ISINUS34962G2084

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -2.06% ARGX argenx SE -1.93% INSM Insmed Inc -0.31% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.